Could Sensus Healthcare, Inc. (SRTS) See a Reversal After Breaking Its 52-Week High?

June 16, 2018 - By Marie Mckinney

The stock of Sensus Healthcare, Inc. (NASDAQ:SRTS) hit a new 52-week high and has $7.70 target or 5.00 % above today’s $7.33 share price. The 6 months bullish chart indicates low risk for the $99.45M company. The 1-year high was reported on Jun, 16 by If the $7.70 price target is reached, the company will be worth $4.97M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 6.39% or $0.44 during the last trading session, reaching $7.33. About 29,886 shares traded or 157.68% up from the average. Sensus Healthcare, Inc. (NASDAQ:SRTS) has risen 75.13% since June 16, 2017 and is uptrending. It has outperformed by 62.56% the S&P500.

Analysts await Sensus Healthcare, Inc. (NASDAQ:SRTS) to report earnings on August, 2. They expect $-0.03 EPS, up 50.00 % or $0.03 from last year’s $-0.06 per share. After $-0.08 actual EPS reported by Sensus Healthcare, Inc. for the previous quarter, Wall Street now forecasts -62.50 % EPS growth.

Another recent and important Sensus Healthcare, Inc. (NASDAQ:SRTS) news was published by which published an article titled: “Sensus Healthcare to Participate in Panel Discussion at the Cantor Fitzgerald Dermatology & Aesthetics Summit” on June 12, 2018.

Sensus Healthcare, Inc. manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. The company has market cap of $99.45 million. It offers SRT-100, a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameter. It currently has negative earnings. The firm also provides Sentinel service program, which offers its clients protection for their SRT-100 and SRT-100 Vision systems.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.